Now available OCREVUS ZUNOVO™

OCREVUS ZUNOVO™ (ocrelizumab and hyaluronidase-ocsq) injection, for subcutaneous use, is a CD20-directed cytolytic antibody indicated for the treatment of:

• Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
• Primary progressive MS, in adults